Registry for patients with cardiac amyloidosis at University Hospital Leipzig
Official title: Cardiac Amyloidosis Registry of University Hospital Leipzig
Run by University of Leipzig · NCT06129656 · Data updated 2026-11-12
This study is collecting information from patients with cardiac amyloidosis at University Hospital Leipzig to better understand the disease and improve treatment and care.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | University of Leipzig Academic / other |
| Locations | 1 site (Leipzig, Saxony) |
| Status | Recruiting |
| Started | May 1, 2023 |
| Main results expected | May 2033 |
| Study ends | May 2033 |
| Registry record updated | November 13, 2023 |
| Trial ID | NCT06129656 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this registry are individuals with a confirmed diagnosis of cardiac amyloidosis.
✕Probably not a fit
Patients who refuse to participate in the registry will not benefit from the data collection and insights generated.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry collects detailed information on patients diagnosed with cardiac amyloidosis at University Hospital Leipzig. It aims to gather data on clinical events, symptoms, imaging results, biomarkers, comorbidities, and treatment outcomes from routine patient management, which are often not captured in randomized clinical trials. By reflecting real-world clinical practice, the registry seeks to enhance understanding of the disease's epidemiology, diagnostic methods, and long-term outcomes. The data collected will also help validate findings from clinical trials and improve treatment implementation and patient monitoring.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights that improve the management and treatment of cardiac amyloidosis, leading to better patient outcomes.
How similar studies have gone: Other clinical registries have successfully provided important real-world data that complements findings from randomized trials, making this approach well-supported.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed cardiac amyloidosis according to current standards Exclusion Criteria: * refusal to participate
Where it's running
-
University Hospital Leipzig
Leipzig, Saxony, Germany Recruiting
Study contacts
- Principal investigator: Daniel Lavall, MD — University of Leipzig
- Study coordinator: Daniel Lavall, MD
- Email: daniel.lavall@medizin.uni-leipzig.de
- Phone: +493419712650
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver and Coagulation Markers in ATTR Cardiac Amyloidosis
This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.
-
Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT
This study tests whether a contrast-enhanced cardiac CT can reliably detect intracardiac thrombi in adults with cardiac amyloidosis.
-
Higher pacemaker rate for people with cardiac amyloidosis
This study will see if temporarily increasing the pacemaker rate improves heart-failure symptoms and exercise tolerance in adults with cardiac amyloidosis who already have pacemakers.
-
Using [64Cu]FBP8 PET/MR to find intracardiac blood clots in cardiac amyloidosis
We'll test whether a [64Cu]FBP8 PET/MR scan can find blood clots inside the heart of people with cardiac amyloidosis who have atrial fibrillation or atrial flutter.
-
Chest pain screening for hidden cardiac amyloidosis
We will test whether men over 65 who have chest pain but no coronary artery disease might have hidden cardiac amyloidosis using blood and urine tests, ECG and echocardiography, bone scintigraphy, and sometimes a heart biopsy.
-
Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies
This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.